Full-Time

Infusion Nurse

RN

Updated on 8/1/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

Compensation Overview

CA$66.4k - CA$132.7k/yr

Langley, BC, Canada + 1 more

More locations: Abbotsford, BC, Canada

In Person

Travel within the designated and surrounding IBUs, including clinic and homecare appointments, is required.

Category
Medical, Clinical & Veterinary (1)
Required Skills
CPR
Medication Administration
Word/Pages/Docs
PALS
Customer Service
ACLS
Patient Education
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Cencora

See people who can refer or advise you

Requirements
  • Relevant experience as a Registered Nurse is required.
  • One year of intravenous initiation experience is required.
  • Current registration with the licensing body and a cardiopulmonary resuscitation certificate are required.
  • Experience in a critical care, emergency, acute care inpatient or outpatient, or homecare setting is required.
  • Proficiency in Microsoft Excel, Microsoft Outlook, Microsoft Word, and other applicable computer programs is required.
  • Access to an internet connection is required.
  • Knowledge of cell phones for making and confirming appointments and assignments, and fax machines, is required.
  • Strong written and verbal communication skills are required.
  • The candidate must be able to work autonomously with little supervision as part of a larger team.
  • The candidate must be able to travel to clinics and homecare appointments within a set geographical boundary.
  • The candidate must demonstrate strong critical thinking and its application.
  • The candidate must demonstrate effective interpersonal and leadership skills.
  • The candidate must demonstrate effective organizational skills and attention to detail.
  • The candidate must demonstrate effective time management and prioritization skills.
  • The candidate must consistently meet deadlines.
  • The candidate must demonstrate excellent problem-solving skills and the ability to resolve issues effectively and efficiently.
  • The candidate must demonstrate excellent presentation skills.
  • The candidate must be self-directed and able to work independently.
  • The candidate must be able to adapt to a fast-paced environment.
  • The candidate must hold and maintain a valid, non-expired, unrestricted driver's license and insurance coverage.
  • The candidate may have daily contact with unilingual English-speaking customers, patients, or peers from cross-functional teams.
Responsibilities
  • Administer medications in specialty clinics and Physician Partnership clinic settings.
  • Assess and monitor pre- and post-injection or infusion treatments as directed by program protocols.
  • Complete necessary documentation based on policies and procedures, College of Nurses requirements, and Innomar ISO accreditation standards of practice.
  • Provide patient and caregiver education based on product monographs and program protocols, individually or in groups.
  • Report adverse events, serious adverse events, and product complaints in accordance with Innomar training and policies and procedures.
  • Provide reliable availability based on the agreed employment agreement to meet the needs of the IBU and the nursing and clinic key performance indicators.
  • Communicate and work effectively among multidisciplinary teams, including case managers, physicians, pharmacy, scheduling, and other departments, to meet established timelines for scheduling appointments and treatments.
  • Communicate with patients and caregivers to set up appointments and drug delivery to homes and clinics.
  • Participate regularly in team web-based meetings and training sessions with the Business Area Manager, Registered Nurse Educator, and Nurse Champion to maintain and enhance professional practice standards.
  • Participate in specialized client-related training as required.
  • Adhere to professional nursing standards prescribed by professional associations and Innomar.
  • Work collaboratively within a multidisciplinary healthcare team, providing oversight and delegation of applicable tasks to Registered Practical Nurses or Licensed Practical Nurses as authorized by the provincial college of nurses.
  • Travel within the designated IBU and surrounding IBUs to meet operational needs.
  • Follow all nursing and clinic standard operating procedures and work instructions.
  • Follow all health and safety standards under the provincial Health and Safety Act.
  • Complete ongoing and annual education training according to the training matrix within specified timeframes.
  • Perform other related duties and tasks as required by Innomar.
Desired Qualifications
  • Advanced knowledge of the pharmaceutical distribution industry.
  • Business and financial acumen.
  • Advanced cardiovascular life support certification.
  • Pediatric advanced life support certification.
  • Multiple sclerosis certification.
  • Canadian Vascular Access Association certification.
  • Experience with central venous lines and ports.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty drug growth lifts mix toward higher-value distribution and services.
  • More manufacturer outsourcing supports commercialization, access, and consulting revenue.
  • Pharmacy automation and reimbursement support can improve margins and customer retention.

What critics are saying

  • PBM-owned pharmacies and home-delivery channels compress Cencora's specialty distribution economics.
  • Generic deflation and customer consolidation pressure spreads in U.S. Healthcare Solutions.
  • Opioid litigation from AmerisourceBergen legacy still threatens cash and management attention.

What makes Cencora unique

  • Largest U.S. drug wholesaler with broad brand, generic, and specialty distribution.
  • International Healthcare Solutions adds global commercialization services beyond basic pharmaceutical distribution.
  • Animal health, patient access, and data analytics widen its service stack.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.